ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Emphasis On Early Disease In Clinical Trials, Early Lung Cancer Detection Seen As “Landmark”

September 19, 1975

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

FY99 Appropriations: Congress Tells NCI To Fund More Research In Prostate Cancer

October 30, 1998

SWOG Seeks NSCLC Patients For Study Of Gender Differences In Lung Cancer

October 28, 2005

Reorganization Of Making Program Is Proposed

June 22, 1990

NCI Launches ALCHEMIST

September 5, 2014